Researchers at VIB and the University of Antwerp have identified a repeat expansion in the GOLGA8A gene as a major genetic risk factor for atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions (aFTLD-U), a rare and previously unexplained subtype of frontotemporal dementia. The findings, published online March 12, 2026 in Nature Genetics, mark the first genetic entry point for a disease that neuropathologists have long diagnosed only after death, at autopsy.
The team, led by Rosa Rademakers of the University of Antwerp, first ran a genome-wide association study comparing 59 pathologically confirmed aFTLD-U cases with 3,153 controls, finding a locus on chromosome 15q14 tagged by the variant rs549846383 (P = 5.85 x 10^-21, odds ratio 26.7). Adding 28 more cases, 3,712 further controls and 3,215 people with other neurodegenerative diseases, and drawing on long-read genome sequencing from 1,715 individuals, the researchers traced the signal to a tandem repeat expansion inside an intron of GOLGA8A, a gene not previously linked to any dementia. Long stretches of a CT-dimer repeat were strongly tied to aFTLD-U, present in close to 60 percent of the confirmed cases the team examined.
The same repeat expansion turned up, at similar length, in some people without aFTLD-U, including unaffected relatives of patients, the authors report, meaning that carrying the expansion is not on its own enough to cause the disease. What the expansion actually does to GOLGA8A, a gene structurally related to Golgi membrane proteins, remains unknown, and roughly 40 percent of the aFTLD-U cases in the study carried no trace of the associated haplotype at all.
Frontotemporal dementia affects, by figures cited in the study, between roughly 0.02 and 0.22 per 1,000 people aged 45 to 64, and aFTLD-U is one of its rarest, sporadic forms, historically confirmed only through clumps of FET family proteins found in brain tissue after death. The authors say the discovery could eventually aid diagnosis and the grouping of patients for research, but they stop short of describing any test or treatment ready for clinical use.